Cidara Therapeutics, Inc. (CDTX)

NASDAQ: CDTX · IEX Real-Time Price · USD
0.837
0.011 (1.32%)
At close: Jan 25, 2022 3:59 PM
0.845
0.008 (0.932%)
After-hours:Jan 25, 2022 4:00 PM EST
Market Cap55.82M
Revenue (ttm)46.08M
Net Income (ttm)-49.19M
Shares Out66.69M
EPS (ttm)-1.00
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume231,018
Open0.810
Previous Close0.826
Day's Range0.800 - 0.850
52-Week Range0.779 - 3.150
Beta1.07
AnalystsBuy
Price Target6.34 (+657.4%)
Earnings DateFeb 23, 2022

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel long-acting anti-infectives for the treatment and prevention of diseases in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbrea...

IndustryBiotechnology
IPO DateApr 15, 2015
CEOJeffrey Stein
Employees79
Stock ExchangeNASDAQ
Ticker SymbolCDTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is 6.34, which is an increase of 657.38% from the latest price.

Price Target
$6.34
(657.38% upside)
Analyst Consensus: Buy

News

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

2 weeks ago - GlobeNewsWire

Cidara Therapeutics Stock Slides Despite Acing Rezafungin Trial In Fungal Infection

Cidara Therapeutics Inc (NASDAQ: CDTX) and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endpoint o...

1 month ago - Benzinga

Cidara Therapeutics and Mundipharma Announce Positive Topline Results from the Global Phase 3 Pivotal ReSTORE Trial o...

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care

1 month ago - GlobeNewsWire

Implied Volatility Surging for Cidara Therapeutics (CDTX) Stock Options

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

1 month ago - Zacks Investment Research

3 Biotech Penny Stocks To Watch With The Stock Market Down Today

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Informa...

Other symbols:CPIXCTIC
1 month ago - PennyStocks

Cidara Therapeutics Named A San Diego Metro Area Top Workplace For The Fifth Consecutive Year

Cidara recognized as the top-ranked biotech therapeutics company based on employee feedback Cidara recognized as the top-ranked biotech therapeutics company based on employee feedback

2 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Reports Q3 Loss, Tops Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 0.00% and 95.74%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Cidara Provides Corporate Update and Reports Third Quarter 2021 Financial Results

SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

2 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Cidara Therapeutics Announces Closing of Concurrent Public Offerings of Common Stock and Preferred Stock and Full Exe...

SAN DIEGO, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

3 months ago - GlobeNewsWire

Cidara Therapeutics Announces Pricing of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

3 months ago - GlobeNewsWire

Cidara Therapeutics Announces Commencement of Concurrent Public Offerings of Common Stock and Preferred Stock

SAN DIEGO, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients f...

3 months ago - GlobeNewsWire

Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021

WASHINGTON, Sept. 30, 2021 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations, today a...

3 months ago - PRNewsWire

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients ...

3 months ago - GlobeNewsWire

Cidara Therapeutics to Host Research and Development Day

Virtual event will highlight the broad potential of the Cloudbreak ® platform and the commercial potential for rezafungin

4 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Q2 Earnings and Revenues Surpass Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of 166.67% and 415.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Cidara Provides Corporate Update and Reports Second Quarter 2021 Financial Results

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

5 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Cidara Therapeutics (CDTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

Cidara Therapeutics to Present New Data for Rezafungin at the International Society for Human and Animal Mycology (IS...

SAN DIEGO, July 27, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

5 months ago - GlobeNewsWire

Cidara Therapeutics Provides Leadership Update

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

6 months ago - GlobeNewsWire

Cidara Therapeutics to Present New Analyses for Rezafungin at the 31st European Congress of Clinical Microbiology and...

SAN DIEGO, June 30, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

6 months ago - GlobeNewsWire

Cidara Therapeutics to Participate in the Raymond James Human Health Innovation Conference

SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

7 months ago - GlobeNewsWire

Cidara to Present at Mycology 2021 Conference

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients...

7 months ago - GlobeNewsWire

Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue Estimates

Cidara Therapeutics (CDTX) delivered earnings and revenue surprises of -129.41% and -83.95%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Cidara Provides Corporate Update and Reports First Quarter 2021 Financial Results

SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients ...

8 months ago - GlobeNewsWire